EVEREST MED.LTD DL-0001 Asset Resilience Ratio
EVEREST MED.LTD DL-0001 asset resilience ratio. EVEREST MED.LTD DL-0001 (6HN) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6HN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of EVEREST MED.LTD DL-0001 (2022–2025)
Asset resilience ratio of EVEREST MED.LTD DL-0001 from 2022 to 2025. This chart shows how EVEREST MED.LTD DL-0001's Asset Resilience Ratio has changed over time. Read EVEREST MED.LTD DL-0001 debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down EVEREST MED.LTD DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of EVEREST MED.LTD DL-0001.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €517.64 Million | 6.13% |
| Total Liquid Assets | €517.64 Million | 6.13% |
Asset Resilience Insights
- Limited Liquidity: EVEREST MED.LTD DL-0001 maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EVEREST MED.LTD DL-0001 Industry Peers by Asset Resilience Ratio
Compare EVEREST MED.LTD DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
EVEREST MED.LTD DL-0001 Asset Resilience Ratio by Year (2022–2025)
EVEREST MED.LTD DL-0001 asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for EVEREST MED.LTD DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.98% | €887.09 Million ≈ $1.04 Billion |
€6.83 Billion ≈ $7.99 Billion |
-1.52pp |
| 2024-12-31 | 14.50% | €718.84 Million ≈ $840.40 Million |
€4.96 Billion ≈ $5.80 Billion |
-17.15pp |
| 2023-12-31 | 31.64% | €1.83 Billion ≈ $2.14 Billion |
€5.77 Billion ≈ $6.75 Billion |
+14.10pp |
| 2022-12-31 | 17.55% | €1.16 Billion ≈ $1.36 Billion |
€6.61 Billion ≈ $7.73 Billion |
-- |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more